Member Info for gixer

From today
https://baijiahao-baidu-com.translate.goog/s?id=1737411645533407707&wfr=spider&for=pc&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

and tomorrows
https://k-sina-com-cn.translate.goog/article_1664221137_6331ffd102001598j.html?_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp#/

Form Slim Formblut

A fair concoction of ingredients but has Fruitflow.
https://www-formslim-com.translate.goog/shop/index.php?sViewport=detail&sArticle=127&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

https://baijiahao.baidu.com/s?id=1736973080228002274&wfr=spider&for=pc

https://www.sohu.com/a/562157133_120311575

Slightly better volume today though.
ADVFN is showing
LSE
Buy 2,751,242 Sell 3,407,943

Aquis
Buy 1,028,105 Sell 0

But yet we still have a sp of only 0.9p
:(

Composition with effect of assisting in reducing blood fat and application thereof

Abstract
The invention relates to a composition with an auxiliary blood fat reducing effect and application thereof. In particular to application of a composition in preparing a medicine or health-care food with the effect of assisting in reducing blood fat, wherein the composition comprises water-soluble tomato concentrate and functional red rice powder. According to the invention, experimental researches show that the water-soluble tomato concentrate and the functional red rice powder have a coordination and synergism effect in the aspect of assisting blood fat reduction, and by compounding the water-soluble tomato concentrate and the functional red rice powder, the levels of triglyceride, cholesterol and low-density lipoprotein can be obviously reduced, so that an excellent effect of assisting blood fat reduction is achieved.
https://patents.google.com/patent/CN114504617A/en?q=%22water+soluble+tomato+concentrate%22&oq=%22water+soluble+tomato+concentrate%22&sort=new

Water-soluble tomato extract with function of improving memory and application thereof

Abstract
The invention discloses a water-soluble tomato extract with a function of improving memory and application thereof, belonging to the technical field of health care and medicine. The active ingredients of the water-soluble tomato extract comprise nucleoside compounds, flavonoid compounds and phenolic acid compounds, the water-soluble tomato extract has the effect of improving memory, can be used for preparing health-care food or medicine for improving memory, takes water as a solvent in the extraction process, is green and environment-friendly, is easy to implement, and has wide market prospect.
https://patents.google.com/patent/CN114617920A/en?q=%22water+soluble+tomato+concentrate%22&oq=%22water+soluble+tomato+concentrate%22&sort=new

Occasional one still popping up.
https://allbusinessadvice-com.translate.goog/health/233.html?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

Another article on by-health international (Australia) regarding cross border e-commerce but this one mentions provexis and fruitflow at the end wrt new product development.

https://www.nutraingredients-asia.com/Article/2021/11/29/For-the-night-owl-BYHEALTH-reports-strong-sales-of-milk-thistle-melatonin-products-in-11.11

A link to support my suggestion on e-commerce from by-health Austria.
https://www.nutraingredients-asia.com/Article/2022/02/07/BYHEALTH-securing-e-comm-success-via-distributor-empire-private-domain-management-in-China

We know by-health won't be selling any ff based products directly in China until they have regulatory approval although that doesn't stop them selling ff as an ingredient.
I wonder if they have looked at cross border e-commerce as a way of launching.

Haemo-in-form ® fluid is a high-quality preparation that supports normal blood platelet aggregation with water-soluble tomato extract and thus contributes to healthy blood flow.
https://www.formmed-shop.de/wirkung/anwendungsgebiet/blutgerinnung/haemo-in-form-fluid?number=2000.1285

Good thoughts BB.

As far as I can tell there are 3 unknowns that make it difficult to workout the financials after the AA

1/ The profit split. 50/50 would be a good guess as that, IMO, would be worst case for PXS under the new agreement. I had always hoped that we were getting as much as 50% of the profit but in real terms this could have been lower meaning our share of the profit under the new agreement could more than double "assuming like for like sales and margins"

2/ The royalty payable to DSM on the gross profit. This is a big unknown.

3/ The fixed level of overhead deduction from sales. Again an unknown but this obviously stops under the new agreement although we are in discussions with "third parties seeking to progress new sales and distribution opportunities" and there would be a cost to this.

My guess is the company will start to see a profit in calendar year 2023 onwards and that's without factoring in any possible sales to By-Health.
BWTFDIK. DYOR. etc. etc. etc.

everhopeful, am I reading the same RNS as you?
As not once is the word "should" included in it.
It does say "From 1 January 2023 the net profit accruing to Provexis on sales of Fruitflow in the calendar year - on a pro-forma basis, assuming like for like sales and margins - would be materially ahead of the net share of the profit that would have accrued to Provexis with like for like sales and margins under the existing 2010 Alliance Agreement; on the same pro-forma basis,"

wellsite, agree there are still plenty of unknowns and there are no answers to the points you highlight.

1/ DSM haven't been binned as such and will still be involved in the sale of Fruitflow along with a new partnership.
2/ Good question. I take it if they think there investment will go up from here then they will hold but if the want to invest in another Co then who knows.
3/ Depends on the patent and results of the study. DSM are interested in it.
4/ The million dollar question is when.

Strangely quiet here (Volume wise) considering the recent news and the fact that we could start seeing a profit from 1/1/2023 onwards.

"A number of DSM's customers for Fruitflow which are set to be transferred to Provexis have been Fruitflow customers for several years, including some distributor customers which sell Fruitflow on to third parties. The Company greatly looks forward to progressing these existing sales relationships, and confirms it will be able to generate new customers for Fruitflow outside the royalty arrangements with DSM, in addition to its existing supply and distribution agreement for Fruitflow with By-Health. The Company is in discussion with a number of third parties seeking to progress new sales and distribution opportunities for Fruitflow, and it can be contacted for all Fruitflow sales enquiries by email at fruitflow@provexis.com."

If the customer is looking for specific formulations then I guess they would still go through dsm.

" Provexis will sell Fruitflow as a straight ingredient to DSM exclusively for use in DSM's Premix Solutions (www.dsm.com/human-nutrition/en/customized-services/customized-solutions/premix-solutions.html) and Market-Ready Solutions (www.dsm.com/human-nutrition/en/customized-services/customized-solutions/market-ready-solutions.html) businesses, with DSM then looking to sell the resulting Premix and Market-Ready Solutions products on to its customers."

Bella6532, RE: "Who makes FF+O caps and box them for PXS...Gixer didn't we think this was a service provided by DSM?"

Yes, IMO the capsule is a generic DSM product but it could be packaged anywhere. By DSM or here in the UK for PXS.

"PXS gets a percentage in the current AA for the FF content of their own FF+O caps. This will be lost in the new deal."
Not sure thats an issue as we will be selling FF to DSM in the first place.

"Servicing existing accounts with FF might not be too difficult but growing new ones will be a hill to climb with existing PXS personnel"
Just thinking out loud but we know there are "prospective customers" in the background ", including some prospective customers which are part of global businesses". Maybe cost has been an issue with some of these prospective customers and with DSM out of the equation a cheaper product may bring them onboard. Who knows????

" (just to remind you, our sales for the year are forecast to be less than half a million quid)"
Not strictly true. Our share of the profit from sales are forecast to be less than half a million quid. Who knows what profit DSM is making from that sales volume but I would guess its more than we get.

Do we know if DSM has "buyer clout" with Indena (manufacturer of FF) or is Fruitflow the only product they manufacture for DSM?

Also,
Who do you think could sell Fruitflow at a lower price. Provexis or PXS and DSM combined.

RE: "Who do you think has more buying power to negotiate price - DSM or PXS??"

Price will be down to volume and not who is buying IMO.

Plenty of cash in the bank atm.
Cash £1.077m at 31 March 2021
https://www.provexis.com/wp-content/uploads/2021/09/Provexis-plc-annual-report-31-Mar-21-FINAL-TYPESIGNED.pdf

The Company expects to release its preliminary results for the year ended 31 March 2022 in September 2022. The Company expects to report total revenue for the year of £426k and an underlying operating loss of £173k. The expected £173k underlying operating loss for the year is 23% ahead of the prior year (2021: an underlying operating loss of £225k) and is an all-time low number for the business.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1597322